Project Grant R44CA254586

Award Date 8/1/21
Completion Date 8/31/25
Dollars Obligated $2.2M
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
This $962,560 Project Grant (R01CA285369) awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope for cervical cancer screening and treatment in low- and middle-income countries (LMICs). The key objectives are to: 1) Modify the existing IRISTM prototype by enhancing the probes and integrating a machine learning-based...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
The National Cancer Institute (NCI) awarded a $957,152 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to GE Medical Systems Information Technologies, Inc. (doing business as GE Healthcare Technology & Innovation Center) to develop an affordable, automated point-of-care (POC) telecytology platform for oral cancer screening in India. The project aims to create a portable system that can scan brush biopsy cytology slides, transmit images to...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $272,835 Project Grant under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program to the University of Arizona. The goal of this 4-year grant is to develop a new Probe-based Light Sheet Microscopy (PLSM) device and evaluate its clinical utility for in vivo imaging of the anal mucosa to aid in anal cancer screening. The research team, which...
The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
This $753,446 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop and evaluate an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in Boston, Hispanic immigrants in Florida, and Hawaiian Natives/Pacific Islanders in Hawaii. The intervention, called DOSE-CC, combines education and quality improvement methods using a performance...
Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...

A NOVEL, LOW-COST, HANDHELD, 3D IMAGING SYSTEM FOR IMPROVED SCREENING OF CERVICAL NEOPLASIA IN RESOURCE LIMITED SETTINGS - ABSTRACT CERVICAL CANCER IS ONE OF THE MOST PREVENTABLE AND TREATABLE FORMS OF CANCER, REFLECTED BY THE FACT THAT ITS INCIDENCE HAS SIGNIFICANTLY FALLEN IN MOST OF THE DEVELOPED WORLD OVER THE PAST 30 YEARS, LARGELY DUE TO EFFECTIVE SCREENING AND TREATMENT PROGRAMS. IN DEVELOPING COUNTRIES AND ALSO IN SOCIO-ECONOMIC DISADVANTAGED AREAS OF DEVELOPED COUNTRIES, MANY WOMEN LACK CONVENIENT ACCESS TO AFFORDABLE AND HIGH-QUALITY PROGRAMS TO SAVE THEIR LIVES. CURRENTLY, MORE THAN A MILLION WOMEN WORLDWIDE HAVE CERVICAL CANCER. MOST OF THESE WOMEN DO NOT HAVE ACCESS TO DIAGNOSES AND TREATMENTS THAT COULD CURE THEM OR PROLONG THEIR LIVES. IN 2012, >500,000 NEW CASES OF CERVICAL CANCER WERE DIAGNOSED WORLDWIDE, AND >250,000 OF THESE WOMEN DIED OF THE DISEASE -- NEARLY 90% IN LOW- TO MIDDLE-INCOME COUNTRIES. DEATHS DUE TO CERVICAL CANCER ARE PROJECTED TO RISE BY ALMOST 25% OVER THE NEXT 10 YEARS WITHOUT PROPER INTERVENTIONS. NEW TECHNOLOGICAL DEVELOPMENTS OFFER THE POTENTIAL TO MAKE COMPREHENSIVE CERVICAL CANCER CARE FEASIBLE AND AFFORDABLE IN LOW- AND MIDDLE-INCOME COUNTRIES, AND TO MITIGATE THE SKYROCKETING HEALTHCARE COSTS IN THE DEVELOPED WORLD. IN RESPONSE, WE HAVE RECENTLY DEVELOPED (THROUGH SUPPORT FROM AN NSF-SBIR AND NIH-SBIR AWARD) A PORTABLE, LOW-COST, SIMPLE-TO-USE, TELEMEDICINE- AND PATIENT-FRIENDLY INNOVATIVE IMAGING SYSTEM THAT CAN HELP ADVANCE TOWARD THE SCREEN-AND-TREAT STRATEGY FOR CERVICAL CANCER PREVENTION ADVOCATED BY THE WORLD HEALTH ORGANIZATION. IN THIS PHASE II STUDY, WE WILL ESTABLISH FEASIBILITY OF OUR SCREENING PROTOCOLS THROUGH A MULTISITE INTERNATIONAL STUDY AND ADVANCE THE OVERALL TECHNOLOGY.

Posted 9/19/23, 12:00 AM